Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation
- PMID: 19152932
- DOI: 10.1016/j.juro.2008.11.014
Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation
Abstract
Purpose: Potassium citrate therapy has become one of the cornerstones of medical stone management. We elucidated the long-term effects of potassium citrate on urinary metabolic profiles and its impact on stone formation rates.
Materials and methods: We performed a retrospective cohort study in patients treated at the Comprehensive Kidney Stone Center at our institution between 2000 and 2006. Patients with pre-therapy and post-therapy 24-hour urinary profiles available who remained on potassium citrate for at least 6 months were included in the analysis.
Results: Of the 1,480 patients with 24-hour urinary profiles 503 met study inclusion criteria. Mean therapy duration was 41 months (range 6 to 168). Overall a significant and durable change in urinary metabolic profiles was noted as soon as 6 months after the onset of therapy. These changes included increased urinary pH (5.90 to 6.46, p <0.0001) and increased urinary citrate (470 to 700 mg a day, p <0.0001). The stone formation rate also significantly decreased after the initiation of potassium citrate from 1.89 to 0.46 stones per year (p <0.0001). There was a 68% remission rate and a 93% decrease in the stone formation rate.
Conclusions: Potassium citrate provides a significant alkali and citraturic response during short-term and long-term therapy with the change in urinary metabolic profiles sustained as long as 14 years of treatment. Moreover, long-term potassium citrate significantly decreases the stone formation rate, confirming its usefulness in patients with recurrent nephrolithiasis.
Similar articles
-
Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis.J Urol. 2007 Apr;177(4):1358-62; discussion 1362; quiz 1591. doi: 10.1016/j.juro.2006.11.058. J Urol. 2007. PMID: 17382731
-
Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation.Urology. 2007 Nov;70(5):856-60. doi: 10.1016/j.urology.2007.06.1115. Epub 2007 Oct 24. Urology. 2007. PMID: 17919696
-
Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation.Urology. 2007 Jun;69(6):1013-6. doi: 10.1016/j.urology.2007.02.008. Urology. 2007. PMID: 17572176 Clinical Trial.
-
Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment.Arch Ital Urol Androl. 2009 Sep;81(3):182-7. Arch Ital Urol Androl. 2009. PMID: 19911682 Review.
-
Citrate and renal calculi: an update.Miner Electrolyte Metab. 1994;20(6):371-7. Miner Electrolyte Metab. 1994. PMID: 7783699 Review.
Cited by
-
Oral citrate supplementation mitigates age-associated pathological intervertebral disc calcification in LG/J mice.bioRxiv [Preprint]. 2024 Jul 19:2024.07.17.604008. doi: 10.1101/2024.07.17.604008. bioRxiv. 2024. PMID: 39071393 Free PMC article. Preprint.
-
Medical treatment of uric acid kidney stones.Can Urol Assoc J. 2024 Nov;18(11):E339-E345. doi: 10.5489/cuaj.8774. Can Urol Assoc J. 2024. PMID: 38976892 Free PMC article.
-
Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization.Adv Sci (Weinh). 2024 Jun;11(21):e2400642. doi: 10.1002/advs.202400642. Epub 2024 Apr 22. Adv Sci (Weinh). 2024. PMID: 38647258 Free PMC article.
-
Urolithiasis in children; The importance of stone localization in treatment and follow-up.Urolithiasis. 2024 Jan 2;52(1):17. doi: 10.1007/s00240-023-01518-3. Urolithiasis. 2024. PMID: 38165472
-
UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.Can Urol Assoc J. 2022 Jun;16(6):175-188. doi: 10.5489/cuaj.7872. Can Urol Assoc J. 2022. PMID: 35623003 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
